Ascentage Pharma soars on deal with cancer drug competitor
The Chinese drug developer put a rocket booster under its share price after enlisting a Japanese rival as a new equity partner and unveiling plans for a U.S. listing Key…
FAST NEWS: Ascentage’s manufacturing center gets EU stamp of approval
The latest: Ascentage Pharma Group International (6855.HK) announced on Tuesday it recently received a zero-deficiency report following a Good Manufacturing Practice (GMP) compliance audit of its global manufacturing center by…
Recent Articles
RELATED ARTICLES
-
BRIEF: Ascentage Pharma gets Chinese regulatory nod for U.S. listing
6855.HK - Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
- Cloudbreak Pharma sets sights on Hong Kong IPO after license deal
-
BRIEF: Ascentage Pharma prices U.S. IPO at 20% discount, to raise up to $130 million
6855.HK
-
Cancer drug maker Biostar shines on Hong Kong market debut
2563.HK
-
Innovent ditches low-value stake sale after investor outcry
1801.HK
